Screening for Latent Tuberculosis (LTB)
作者： McNally, Do, Facp, Facg, Peter R.
DOI:
关键词:
摘要: Life threatening M. tuberculosis (MTB) infection is a dreaded complication and concern of immune suppression therapy. Anti-TNFα therapy for inflammatory bowel disease (IBD) carries significant risk activation MTB. All IBD patients must be carefully screened active or latent MTB before initiation Recent advances in detection using INF-γ Release Assays, offer clinicians new valuable tool to diminish the among treated with
vhjoe.org 参考文章(23)
Gerald H Mazurek, John Jereb, Andrew Vernon, Phillip LoBue, Stefan Goldberg, Kenneth Castro, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC), Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. ,vol. 59, pp. 1- 25 ,(2010)
George W. Comstock, Robert N. Philip, Lydia B. Edwards, William A. Winn, A COMPARISON IN THE UNITED STATES OF AMERICA OF TWO TUBERCULINS, PPD-S AND RT 23. Bulletin of The World Health Organization. ,vol. 31, pp. 161- 170 ,(1964)
Asher Kornbluth, Infliximab approved for use in Crohn's disease: A report on the fda gi advisory committee conference Inflammatory Bowel Diseases. ,vol. 4, pp. 328- 329 ,(1998) , 10.1002/IBD.3780040415
Hendrik M. van Dullemen, Sander J.H. van Deventer, Daan W. Hommes, Hannie A. Bijl, Jaap Jansen, Guido N.J. Tytgat, James Woody, Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology. ,vol. 109, pp. 129- 135 ,(1995) , 10.1016/0016-5085(95)90277-5
Josh Marehbian, H Michael Arrighi, Steve Hass, Haijun Tian, William J Sandborn, Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. The American Journal of Gastroenterology. ,vol. 104, pp. 2524- 2533 ,(2009) , 10.1038/AJG.2009.322
Mary Glenn Vreeland, Stephen B. Hanauer, Russell D. Cohen, Russell V. Becker, Leanne R. Larson, Advances in the management of Crohn's disease: economic and clinical potential of infliximab Clinical Therapeutics. ,vol. 20, pp. 1009- 1028 ,(1998) , 10.1016/S0149-2918(98)80082-9
R. E. Huebner, M. F. Schein, J. B. Bass, The tuberculin skin test Clinical Infectious Diseases. ,vol. 17, pp. 968- 975 ,(1993) , 10.1093/CLINIDS/17.6.968
Alain M. Schoepfer, Beatrice Flogerzi, Silvia Fallegger, Thomas Schaffer, Stefan Mueller, Laurent Nicod, Frank Seibold, Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease The American Journal of Gastroenterology. ,vol. 103, pp. 2799- 2806 ,(2008) , 10.1111/J.1572-0241.2008.02050.X
James D. Lewis, Joel M. Gelfand, Andrea B. Troxel, Kimberly A. Forde, Craig Newcomb, Hopiy Kim, David J. Margolis, Brian L. Strom, Immunosuppressant medications and mortality in inflammatory bowel disease. The American Journal of Gastroenterology. ,vol. 103, pp. 1428- 1435 ,(2008) , 10.1111/J.1572-0241.2008.01836.X
Joseph Keane, Sharon Gershon, Robert P. Wise, Elizabeth Mirabile-Levens, John Kasznica, William D. Schwieterman, Jeffrey N. Siegel, M. Miles Braun, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent The New England Journal of Medicine. ,vol. 345, pp. 1098- 1104 ,(2001) , 10.1056/NEJMOA011110